Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis - Quiz - MDSpire

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

  • By

  • Mengjiao Lu

  • Lei Yuan

  • Junjie Liu

  • Yifeng Dou

  • Jinguo Cui

  • July 15, 2026

Share

Original Source(s)

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

  • by Mengjiao Lu, Lei Yuan, Junjie Liu, Yifeng Dou, Jinguo Cui

  • July 15, 2026

Related Content

Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer

Small intestinal metastasis of triple-negative breast cancer mimicking lymphoma: imaging findings and case report

Surfactant protein D: prognostic insights and emerging therapeutic roles in cancer